Primary prevention with over-the-counter statins: A cautionary tale

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 3, 2005, Pages 218-220

  Davidoff, Frank ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER INJURY; LOW DRUG DOSE; MUSCLE INJURY; NOTE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS;

CARDIOVASCULAR DISEASES; DRUGS, NON-PRESCRIPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEGISLATION, DRUG; PATIENT EDUCATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 24344476020     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.06.001     Document Type: Note

References (4)

1. B.L. Strom Statins and over-the-counter availability N Engl J Med 352 2005 1403 1405
2. Porter E. Choice is good. Yes, no, or maybe? The New York Times 2005 Mar 27;Sect 4:12.
3. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
4. L.A. Prosser, A.A. Stinnett, P.A. Goldman, L.W. Williams, M.G.M. Hunink, L. Goldman Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics Ann Intern Med 132 2000 769 779